Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 1/20 | 0.49 |
| ▸ | HTR1D | P28221 | 1/20 | 0.48 |
| ▸ | HTR1B | P28222 | 1/20 | 0.48 |
| ▸ | GAA | P10253 | 1/20 | 0.47 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.45 |
| ▸ | TSHR | P16473 | 1/20 | 0.45 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.45 |
| ▸ | NPY1R | P25929 | 1/20 | 0.45 |
| ▸ | NPY2R | P49146 | 1/20 | 0.45 |
| ▸ | CYP11B1 | P15538 | 1/20 | 0.45 |
| ▸ | CYP11B2 | P19099 | 1/20 | 0.45 |
| ▸ | MAPT | P10636 | 1/20 | 0.43 |
| ▸ | ATM | Q13315 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1987035 | 0.82 | KDM4E (0.54) | LMNAGAASMN1; SMN2ALDH1A1KDM4E | |
| SCHEMBL18585107 | 0.81 | CYP11B1 (0.64) | ALDH1A1KDM4ECYP11B1CYP11B2MAPT | |
| SCHEMBL1987646 | 0.79 | LMNA (0.54) | LMNAHTR1DHTR1BGAASMN1; SMN2 | |
| SCHEMBL29751809 | 0.79 | POLB (0.48) | SMN1; SMN2ALDH1A1CYP11B1CYP11B2MAPT | |
| SCHEMBL1583614 | 0.79 | POLB (0.48) | SMN1; SMN2ALDH1A1CYP11B1CYP11B2MAPT | |
| SCHEMBL18034614 | 0.78 | NPC1 (0.50) | LMNASMN1; SMN2ALDH1A1KDM4ECYP11B1 | |
| SCHEMBL16935311 | 0.77 | NPC1 (0.55) | LMNASMN1; SMN2ALDH1A1KDM4ECYP11B1 | |
| SCHEMBL3665876 | 0.74 | LMNA (0.49) | LMNAHTR1DHTR1BGAASMN1; SMN2 | |
| SCHEMBL15508187 | 0.74 | NPC1 (0.50) | LMNASMN1; SMN2ALDH1A1MAPT | |
| SCHEMBL29151899 | 0.74 | MAPT (0.52) | LMNASMN1; SMN2MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110150833-A1 | BENZOPYRANS AND ANALOGS AS RHO KINASE INHIBITORS | THE SCRIPPS RESEARCH INSTITUTE (US) | 2011-06-23 | — | — | US | disclosed |
| EP-2234618-A1 | BENZOPYRANS AND ANALOGS AS RHO KINASE INHIBITORS | The Scripps Research Institute (US) | 2010-10-06 | — | — | EP | disclosed |
| WO-2009079008-A1 | BENZOPYRANS AND ANALOGS AS RHO KINASE INHIBITORS | FENG YANGBO (US) | 2009-06-25 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110150833-A1 | BENZOPYRANS AND ANALOGS AS RHO KINASE INHIBITORS | ROCK1, RHOA, RHOT2 | LMNA 2482/4885HTR1D 3432/4885HTR1B 3948/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.